NKY 80 (Synonyms: Adenylyl Cyclase Type V Inhibitor) |
| カタログ番号GC17177 |
NKY 80 は、V 型、III 型、II 型の IC50 がそれぞれ 8.3 μM、132 μM、1.7 mM の、強力で選択的かつ非競合的なアデニリル シクラーゼ (AC) V 型アイソフォーム阻害剤です。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 299442-43-6
Sample solution is provided at 25 µL, 10mM.
評判の良い論文で引用されたGlpBio製品
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Product Documents
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cas No. | 299442-43-6 | SDF | |
| 同義語 | Adenylyl Cyclase Type V Inhibitor | ||
| Chemical Name | (S)-2-amino-7-(furan-2-yl)-7,8-dihydroquinazolin-5(6H)-one | ||
| Canonical SMILES | O=C1C[C@@H](C2=CC=CO2)CC3=NC(N)=NC=C31 | ||
| Formula | C12H11N3O2 | M.Wt | 229.23 |
| 溶解度 | DMF: 10 mg/ml,DMF:PBS(pH 7.2)(1:1): 0.5 mg/ml,DMSO: 10 mg/ml,Ethanol: 0.25 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
Complete Stock Solution Preparation Table
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 4.3624 mL | 21.8122 mL | 43.6243 mL |
| 5 mM | 0.8725 mL | 4.3624 mL | 8.7249 mL |
| 10 mM | 0.4362 mL | 2.1812 mL | 4.3624 mL |
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Related Products
- GC15745 Mps1-IN-2
- GC10774 CPI-455
- GC35347 Angelol B
- GC44159 MEP-FUBICA
- GC40094 all-trans Retinoic Acid-d5
- GC31018 NEO 376 (SPI-376)
- GC10050 Almorexant hydrochloride
- GC11424 Valproic acid
- GC33570 2-γ-Linolenoyl-1,3-dilinoleoyl-sn-glycerol
- GN10550 Neosperidin dihydrochalcone
- GC12417 KW 3902
- GC30903 Fabomotizole hydrochloride (CM346 hydrochloride)
- GC18663 Leukotriene C4
- GC61325 Tetradecanedioic acid
- GC16405 Safingol
- GC41217 1-Naphthoic Acid
- GC41289 U-75302
レビュー
Average Rating: 5 ★★★★★ (Based on Reviews and 40 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *